DREAMM-7: Belamaf plus bortezomib and dexamethasone outperforms comparator therapy

In patients with multiple myeloma, the disease is often refractory to first-line triple or quadruple therapies. The result: a relapse occurs. Therefore, effective second-line therapy combinations are needed that include new treatment approaches.